XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.21.1

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes) | 6 Months Ended
--- | ---
Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2021:
| Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total
| (in millions)
Goodwill as of October 31, 2020 | $ | 1,441 |  |  | $ | 1,599 |  |  | $ | 562 |  |  | $ | 3,602 |
Foreign currency translation impact | 9 |  |  | 3 |  |  | 5 |  |  | 17 |
Goodwill arising from acquisitions and adjustments | — |  |  | 435 |  |  | — |  |  | 435 |
Goodwill as of April 30, 2021 | $ | 1,450 |  |  | $ | 2,037 |  |  | $ | 567 |  |  | $ | 4,054 |
The component parts of other intangible assets as of April 30, 2021 and October 31, 2020 are shown in the table below:
| Other Intangible Assets
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Book Value
| (in millions)
As of October 31, 2020 |  |  |  |  |
Purchased technology | $ | 1,429 |  |  | $ | 863 |  |  | $ | 566 |
Trademark/Tradename | 196 |  |  | 117 |  |  | 79 |
Customer relationships | 330 |  |  | 158 |  |  | 172 |
Third-party technology and licenses | 11 |  |  | 7 |  |  | 4 |
Total amortizable intangible assets | 1,966 |  |  | 1,145 |  |  | 821 |
In-Process R&D | 10 |  |  | — |  |  | 10 |
Total | $ | 1,976 |  |  | $ | 1,145 |  |  | $ | 831 |
As of April 30, 2021 |  |  |  |  |
Purchased technology | $ | 1,661 |  |  | $ | 916 |  |  | $ | 745 |
Backlog | 8 |  |  | — |  |  | 8 |
Trademark/Tradename | 196 |  |  | 125 |  |  | 71 |
Customer relationships | 360 |  |  | 193 |  |  | 167 |
Third-party technology and licenses | 11 |  |  | 8 |  |  | 3 |
Total amortizable intangible assets | 2,236 |  |  | 1,242 |  |  | 994 |
In-Process R&D | 11 |  |  | — |  |  | 11 |
Total | $ | 2,247 |  |  | $ | 1,242 |  |  | $ | 1,005 |
On April 15, 2021 we completed the acquisition of privately-owned Resolution Bioscience, Inc., a biotechnology company focused on the development and commercialization of next-generation sequencing-based ("NGS") precision oncology solutions, for $550 million cash plus potential future contingent payments of up to $145 million upon the achievement of certain milestones which are based on certain revenue and technical targets. Resolution Bioscience complements and expands our capabilities in NGS-based cancer diagnostics and provides us with innovative technology to further serve the needs of the fast-growing precision medicine market. As a result of this acquisition, we recorded a short-term liability of $47 million in other accrued liabilities and a long-term liability of $49 million in other long-term liabilities on our condensed consolidated balance sheet which reflects the estimated fair value of the potential future contingent payments. We also recorded additions to goodwill of $435 million and additions to other intangible assets of $263 million during the six months ended April 30, 2021. Due to the timing of the close, the valuation of the tangible and intangible assets and related tax impacts and contingent consideration of this acquisition is preliminary and we anticipate will be completed by our fiscal year end. During the six months ended April 30, 2021, other intangible assets in total increased $1 million due to the impact of foreign currency translation. In general, for United States federal tax purposes, goodwill from asset purchases is deductible; however, any goodwill created as part of a stock acquisition is not deductible. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three and six months ended April 30, 2021 and 2020 we did not identify any triggering events or circumstances, including impacts due to COVID-19, which would indicate an impairment of goodwill. During the three and six months ended April 30, 2021, there were no indicators of impairments of indefinite-lived intangible assets. During the three and six months ended April 30, 2020, we recorded an impairment of in-process research and development of $90 million related to the shut-down of our sequencer development program in our diagnostics and genomics segment. Amortization expense of intangible assets was $45 million and $90 million for the three and six months ended April 30, 2021, respectively. Amortization expense of intangible assets was $47 million and $95 million for the three and six months ended April 30, 2020, respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2021 and for each of the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense: |
(in millions) |
Remainder of 2021 | $ | 99 |
2022 | $ | 181 |
2023 | $ | 133 |
2024 | $ | 112 |
2025 | $ | 86 |
2026 | $ | 56 |
Thereafter | $ | 327 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration